Mode of action of trimetazidine and other new metabolic agents in the treatment of ischemic heart disease

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 7, Issue 1, 2003, Pages 91-96

  Lopaschuk, G D ^a   Marzilli, M ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; CARNITINE DERIVATIVE; DICHLOROACETIC ACID; DILTIAZEM; ENZYME INHIBITOR; ETOMOXIR; FATTY ACID; GLUCOSE; METOPROLOL; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE INHIBITOR; RANOLAZINE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANAEROBIC METABOLISM; ANGINA PECTORIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFECT; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; TISSUE INJURY;

EID: 0038809982     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925320300700116     Document Type: Conference Paper

References (45)

1. Neely JR, Morgan HE: Relationship between carbohydrate metabolism and energy balance of heart muscle. Ann Rev Physiol 36:413-459, 1974.
2. Opie LH, King LM: Glucose and glycogen utilization in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol Cell Biochem 180:3-26, 1998.
3. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG: Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Cardiovasc Res 33:243-25, 1997.
4. Taegtmeyer H: Energy substrate metabolism as target for pharmacotherapy in ischaemic and reperfused heart muscle. Heart and Metabolism 1:5-9, 1998.
5. Lopaschuk GD, Belke DD, Gamble J, Itoi T, et al: Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochem Biophys Acta 1213:263-276, 1994.
6. Opie L: The Heart: Physiology, From Cell to Circulation. Philadelphia: Lippincott-Raven, 1998.
7. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD: High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513-17520, 1995.
8. Saddik M, Lopaschuk GD: Myocardial triglyceride turnover during reperfusion of isolated rat hearts subjected to a transient period of global ischemia. J Biol Chem 267:3825-3831, 1991.
9. Liedtke AJ: Alterations in carbohydrate and lipid metabolism in the acutely ischaemic heart. Prog Cardiovasc Dis 23:321-326, 1981.
10. Liu B, Clanachan AS, Schulz, Lopaschuk GD: Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 79:940-948, 1996.
11. 2 during reperfusion of ischemic hearts. Am J Physiol 270:H72-H80, 1996.
12. Orchard CH, Kentish JC: Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol 258:C967-C981, 1990.
13. Lopaschuk GD, Spafford M, Davies NJ, Wall SR: Glucose and palmitate oxidation in isolated working rat hearts reperfused following a period of transient global ischemia. Circ Res 66:546-553, 1989.
14. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet 343:155-158, 1994.
15. Mueller HS, Ayres ST: Metabolic responses of the heart in acute myocardial infarction in man. Am J Cardiol 42:363-371, 1978.
16. Lopaschuk GD, Collins-Nakai R, Olley PM, et al: Plasma fatty acid levels in infants and adults following myocardial ischemia. Am Heart J 128:61-67, 1995.
17. Benzi RH, Lerch R: Dissociation between contractile function and oxidative metabolism in postischemic myocardium. Circ Res 71:567-576, 1991.
18. Lopaschuk GD, Rebeyka IM, Allard MF: Metabolic modulation. A means to mend a broken heart. Circulation 105:140-142, 2002.
19. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P: Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 26:949-958, 1994.
20. Lopaschuk GD, Kozak R: Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 30:A112, 1998.
21. Kantor PF, Lucien A, Kozak R, Lopaschuk, GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 86:580-588, 2000.
22. El Banani H, Bernard M, Baertz D, et al: Changes in intracellular sodium and pH during ischemia-reperfusion are attenuated by trimetazidine: Comparison between low- and zero-flow ischaemia. Cardiovasc Res 47:688-696, 2000.
23. d'Alache P, Clauser P, Morel M, Guathier V: Assessment with potential mapping of the cardiac protective effect of a drug. Example of trimetazidine. J Pharmacol Methods 26:43-51, 1992.
24. Libersa C, Honore E, Adamantidis M, Rouet E, et al: Antiischemic effect of trimetazidine - enzymatic and electrical response in a model of in vitro myocardial ischemia. Cardiovasc Drugs Ther 4:808-809, 1990.
25. Boucher FR, Hearse DJ, Opie LH: Effects of trimetazidine on ischemic contracture in isolated perfused rat heart. J Cardiovas Pharmacol 24:45-49, 1994.
26. El Banani H, Bernard M, Cozzone P, James F, et al: Ionic and metabolic imbalance as potential factors of ischemia reperfusion injury. Am J Cardiol 82:25K-29K, 1998.
27. Mehrotra TN, Bassadone ET: Trimetazidine in the treatment of angina pectoris. British J Clin Prac 21(11):553-554, 1967.
28. Brodbin P, O'Conner CA: Trimetazidine in the treatment of angina pectoris. British J Clin Prac 22(9):395-396, 1967.
29. Sellier P: The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. Archives des Maladies du Coeur et des Vaisseaux. 79(9):1331-1336, 1986.
30. Sellier P, Audouin P, Payen B, Duong TC, et al: Ergometric effects of a single administration of trimetazidine. Presse Medicale 15(35):1771-1.774, 1986.
31. Passerson J: Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study. Presse Medicale 15(35):1775-1778, 1986.
32. Gallet M: Clinical effectiveness of trimetazidine in stable effort angina. A double blind versus placebo controlled study. Presse Medicale 15(35):1779-1782, 1986.
33. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P: Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 37:279-288, 1994.
34. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, et al: Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther 4(suppl 4):853-859, 1990.
35. Levy S: Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol 76(6):12B-16B, 1995.
36. Szwed H, Sadowski Z, Elikowski W, et al: Combination treatment in stable effort angina using trimetazidine and metroprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J 22:2267-2274, 2001.
37. Kober G, Buck T, Sievert H, Vallbracht C: Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of Trimetazidine. Eur Heart J 13:1109-1115, 1992.
38. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD: Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135-142, 1996.
39. McVeigh JJ, Lopaschuk GD: Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 29: H1079-H1085, 1990.
40. Bersin RM, Wolfe C, Kwasman N, Lau D, et al: Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23:1617-1624, 1994.
41. Schonekess BO, Allard MF, Lopaschuk GD: Propionyl-L-carnitine improvement of hypertrophied heart is accompanied by an increase in carbohydrate oxidation. Circ Res 77:726-734, 1995.
42. Ferrari R, Anard I: Utilization of propionyl-L-carnitine for the treatment of heart failure, in De Jong JW, Ferrari R (eds): The Carnitine System: A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1995, pp 323-336.
43. Paulson DJ, Shug AL: Experimental evidence for the antiischemic effects of L-carnitine, in De Jong JW, Ferrari R (eds): The Carnitine System: A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1995.
44. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD: The beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 87:972-98, 1993.
45. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, et al, on behalf of the CEDIM investigators: Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM). J Am Coll Cardiol 26:380-387, 1995.